Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym015 in advanced solid tumors
NCT02648724Phase 2Completed
- Sponsor
- Symphogen
- Start
- Mar 2016
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of sym015 in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Symphogen. Started Mar 2016; status: completed.
02
Drugs
sym015
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02648724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648724.